Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on August 26, 2025, at 15:00 in Zhuhai City [1][2] - Shareholders can vote either in person or via online voting through the Shenzhen Stock Exchange [1][2] Voting Procedures - Shareholders must choose either on-site voting or online voting, with duplicate votes being counted as the first vote [2] - Voting will be conducted through the Shenzhen Stock Exchange trading system and internet voting system [1][5] Agenda Items - The meeting will include proposals that have been approved by the company's board, with specific voting methods outlined for each proposal [3][12] - Proposals 1 and 2 will use cumulative voting, while proposals 3, 4, and 5 require a special resolution with at least 2/3 of the valid votes [3][12] Registration and Attendance - Shareholders must present relevant identification documents for registration [3][4] - Proxy representatives do not need to be shareholders but must provide proper authorization [2][3] Online Voting Details - The company provides a platform for online voting, with specific instructions for participation [5][7] - The online voting system will be available during designated hours on the day of the meeting [1][10]

Core Viewpoint - The company, SAILONG Pharmaceutical Group Co., Ltd., has announced the nomination of candidates for both non-independent and independent directors to be elected at the upcoming shareholders' meeting, ensuring compliance with relevant laws and regulations [1][2]. Summary by Category Non-Independent Directors - The board has approved the nomination of five candidates for non-independent directors: Mr. Jia Jinbin, Mr. Chen Ke, Mr. Chen Dunfei, Mr. Zhang Guangyang, and Ms. Li Tongyao, with their terms starting from the date of election by the shareholders [1][2]. - All nominated non-independent directors do not hold shares in the company and have no relationships with shareholders holding more than 5% of the company's shares [3][4][6][10]. Independent Directors - The board has also approved the nomination of three candidates for independent directors: Ms. Wang Shufang, Mr. Zhang Jianmin, and Mr. Zhang Kai, pending approval at the shareholders' meeting [1][2]. - The independent director candidates have obtained the necessary qualifications and training, with Ms. Wang Shufang already holding an independent director qualification certificate [2][11][12][13]. - The election process will follow a cumulative voting system, and the independent directors must be filed with the Shenzhen Stock Exchange without objection before being submitted for shareholder approval [2]. Compliance and Qualifications - All nominated candidates meet the legal and regulatory requirements for their positions, including not having any penalties from regulatory bodies or being listed as untrustworthy by the courts [3][4][11][12][13]. - The company ensures that the number of independent directors will be no less than one-third of the total board members, and no independent director will have served more than six consecutive years [2].

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-054 赛隆药业集团股份有限公司 独立董事候选人声明与承诺 声明人 张凯作为赛隆药业集团股份有限公司第四届董事会独立董事候选人， 已充分了解并同意由提名人海南雅亿共赢科技合伙企业（有限合伙）提名为赛隆 药业集团股份有限公司（以下简称该公司）第四届董事会独立董事候选人。现公 开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相 关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过赛隆药业集团股份有限公司第四届董事会提名委员会或者 独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办 ...

关于公司董事长、董事及部分高级管理人员辞职 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-047 赛隆药业集团股份有限公司 的公告 张旭女士申请辞去公司董事、战略决策委员会委员职务，辞去上述职务后张 旭女士继续担任公司副总裁、董事会秘书。截至本公告披露日，张旭女士未持有 公司股份，不存在应履行而未履行的承诺事项。 邓拥军先生申请辞去公司董事、战略决策委员会委员职务，辞去上述职务后 邓拥军先生继续在公司工作。截至本公告披露日，邓拥军先生未持有公司股份， 不存在应履行而未履行的承诺事项。 潘传云先生申请辞去公司独立董事、审计委员会主任委员、提名委员会委员 职务，其辞职报告自公司股东会选举产生新任独立董事之日起生效，辞去上述职 务后潘传云先生不再担任公司任何职务。截至本公告披露日，潘传云先生未持有 公司股份，不存在应履行而未履行的承诺事项。 陈小辛先生申请辞去公司独立董事、提名委员会主任委员、薪酬与考核委员 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 因赛隆药业集团股份有限公司（以下简称"公司"）控制权已发生变更，公 司于近日收到董事长兼总 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-052 赛隆药业集团股份有限公司 独立董事候选人声明与承诺 声明人 王淑芳作为赛隆药业集团股份有限公司第四届董事会独立董事候选 人，已充分了解并同意由提名人海南雅亿共赢科技合伙企业（有限合伙）提名为 赛隆药业集团股份有限公司（以下简称该公司）第四届董事会独立董事候选人。 现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符 合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独 立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过赛隆药业集团股份有限公司第四届董事会提名委员会或者 独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理 ...

董事会 附件：陈科先生简历 该事项已经公司第四届董事会提名委员会 2025 年第一次会议审议通过。 陈科先生简历详见附件。 特此公告。 赛隆药业集团股份有限公司 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-050 赛隆药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于 2025 年 8 月 10 日召开 了第四届董事会第十次会议，审议通过了《关于聘任公司总裁的议案》，公司董 事会同意聘任陈科先生担任公司总裁，任期自本次董事会会议审议通过之日起至 第四届董事会届满之日止。 陈科先生：1986 年出生，本科学历，中国注册会计师，中国国籍，有香港居 民身份证。曾就职于毕马威华振会计师事务所（有限合伙）、北京奇虎科技有限 公司，中投信联(深圳)资产管理有限公司，曾任苏州倾襄投资中心（有限合伙） 执行事务合伙人，现任苏州互襄投资中心（有限合伙）执行事务合伙人委派代表、 投资合伙人。 截至目前，陈科先生未持有公司股份，与持有公司 5%以上股份的股东、公司 其他董事、高级管理人员之间不 ...

Group 1 - The company held its first meeting of the Nomination Committee for the fourth board of directors in 2025, reviewing and providing opinions on relevant matters [1] - The committee reviewed the proposals for the election of non-independent and independent directors, confirming that the candidates meet the qualifications and do not fall under any disqualifying conditions as per relevant laws and regulations [1][2] - The candidates for the non-independent director position include Ms. Li Tongyao, while the independent director candidates are Ms. Wang Shufang, Mr. Zhang Jianmin, and Mr. Zhang Kai [2] Group 2 - The committee reviewed the proposal for the appointment of Mr. Chen Ke as the company's president, finding that he meets the qualifications as per the Company Law and the company's articles of association, with no disqualifying conditions identified [2] - The committee agreed to submit the proposal for Mr. Chen Ke's appointment to the board of directors for further consideration [2]

Core Viewpoint - The independent director candidate Wang Shufang has been nominated for the fourth board of directors of Sailong Pharmaceutical Group Co., Ltd. by Hainan Yayi Win-Win Technology Partnership (Limited Partnership) [1] Group 1: Nomination Process - The nomination was made after a thorough understanding of the candidate's professional background, education, qualifications, work experience, and any significant dishonesty records [1] - The candidate has agreed in writing to serve as an independent director [1] Group 2: Compliance with Regulations - The candidate has passed the qualification review by the nomination committee of the board of directors [2] - The candidate meets the qualifications and conditions for independent directors as stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange [2][3] - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [5] Group 3: Independence and Conflict of Interest - The candidate does not have any relationships that could affect their independent performance [1][2] - The candidate and their immediate family members do not hold more than 1% of the company's issued shares [5][6] - The candidate has no significant business dealings with the company or its controlling shareholders [6][7] Group 4: Professional Experience and Knowledge - The candidate possesses basic knowledge related to the operation of listed companies and has over five years of relevant work experience in law, economics, management, accounting, or finance [5][6] - If nominated as an accounting professional, the candidate must have at least a CPA qualification or equivalent advanced degree [5] Group 5: Commitment and Accountability - The nominator guarantees the truthfulness and completeness of the statements made in the nomination [9] - The nominator authorizes the company secretary to submit the declaration to the Shenzhen Stock Exchange [9]

起诉公司，公司可以起诉股东、董事、监事和高 公司，公司可以起诉股东、董事和高级管理人 | 赛隆药业集团股份有限公司 | | | --- | --- | | 《公司章程》修正案 | | | 赛隆药业集团股份有限公司（以下简称"公司"）第四届董事会第十次会议审议通过了 | | | 《关于修订 <公司章程> 的议案》。根据《中华人民共和国公司法》 | | | 《上市公司章程指引（2025 | | | 2024 12 27 年修订）》及中国证券监督管理委员会于 年 月 日发布的《关于新 | <公司法> 配套 | | 制度规则实施相关过渡期安排》相关法律法规的规定，结合公司的实际情况及需求，公司拟 | | | 对《公司章程》相应条款进行修订，具体情况如下： | | | 修订前 修订后 | | | 全文 股东大会 全文 股东会 | | | 第一条 为维护赛隆药业集团股份有限公司 第一条 为维护赛隆药业集团股份有限公司 | | | （以下简称"公司"）、股东和债权人的合法权 （以下简称"公司"）、股东、职工和债权人的合 | | | 益，规范公司的组织和行为，根据《中华人民共 法权益，规范公司的组织和行为，根据《中华 | | ...

Core Points - The articles outline the articles of association for Sailong Pharmaceutical Group Co., Ltd, detailing the company's legal framework, governance structure, and operational guidelines [1][2][3]. Group 1: Company Overview - Sailong Pharmaceutical Group Co., Ltd is established as a joint-stock company in accordance with the Company Law and other relevant regulations [1]. - The registered capital of the company is RMB 176.6 million [2]. - The company is located at 31 Nanwan North Road, Xiangzhou District, Zhuhai, Guangdong Province, with a postal code of 519060 [1]. Group 2: Governance Structure - The legal representative of the company is elected by the board of directors and must be a director or the general manager [2]. - The company’s assets are divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [2][3]. - The articles of association serve as a legally binding document for the company, shareholders, directors, and senior management [2]. Group 3: Business Objectives and Scope - The company's business objective is to enhance management levels and core competitiveness while providing quality services to customers and maximizing shareholder value [3]. - The business scope includes drug production, wholesale, food production, medical devices, and related services, subject to legal approvals [3][4]. Group 4: Share Issuance and Management - The company issues shares in the form of stocks, with each share having a par value of RMB 1 [5][6]. - The total number of shares issued by the company is 176 million, all of which are ordinary shares [5]. - The company cannot provide financial assistance for the purchase of its shares in any form [5]. Group 5: Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, attend meetings, supervise company operations, and transfer their shares [9][10]. - Shareholders must comply with laws and the articles of association, and they are liable for any damages caused by the abuse of their rights [13][39]. - The company must maintain transparency and provide necessary information to shareholders regarding their rights and the company's operations [10][12]. Group 6: Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [18][19]. - Shareholder proposals must be submitted in writing and can be made by shareholders holding at least 1% of the shares [23][24]. - Decisions at shareholder meetings require a majority or supermajority vote, depending on the nature of the resolution [78][80].